Palatin Technologies, Inc. (PTN)Healthcare | Biotechnology | Monmouth Junction, United States | NYSE American
22.10 USD
-0.32
(-1.449%) ⇩
(April 21, 2026, 12:05 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:09 p.m. EDT
Venue death spirals: Palatin's ex-NYSE American transition to the OTC Pink signals severe immediate liquidity risk and delisting fees, outweighing the positive impact of the $18.2M capital raise; despite a bullish 52-week average and technical bounce near $22, the loss of public listing status and deteriorating fundamentals (-70% ROA) suggests this is a high-rerisk, diminishing-asset trap rather than a valid entry. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.137374 |
| AutoETS | 0.144697 |
| AutoARIMA | 0.144988 |
| AutoTheta | 0.365633 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 6.23 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.307 |
| Excess Kurtosis | -1.11 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.042 |
| Revenue per Share | 7.385 |
| Market Cap | 39,165,600 |
| Forward P/E | -8.98 |
| Beta | -0.15 |
| Profit Margins | -107.41% |
| Website | https://palatin.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.1019049 |
| Address1 | 11 Deer Park Drive |
| Address2 | Suite 204 |
| All Time High | 128,125.0 |
| All Time Low | 2.0 |
| Ask | 22.69 |
| Ask Size | 100 |
| Average Daily Volume10 Day | 19,560 |
| Average Daily Volume3 Month | 19,052 |
| Average Volume | 19,052 |
| Average Volume10Days | 19,560 |
| Beta | -0.147 |
| Bid | 21.66 |
| Bid Size | 200 |
| Book Value | 6.525 |
| City | Monmouth Junction |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 22.1 |
| Current Ratio | 2.758 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 22.33 |
| Day Low | 22.1 |
| Debt To Equity | 3.042 |
| Display Name | Palatin |
| Ebitda | -12,364,254 |
| Ebitda Margins | -1.37939 |
| Enterprise To Ebitda | -2.021 |
| Enterprise To Revenue | 2.787 |
| Enterprise Value | 24,985,132 |
| Eps Current Year | -3.28 |
| Eps Forward | -2.46 |
| Eps Trailing Twelve Months | -8.26 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 20.2724 |
| Fifty Day Average Change | 1.8276005 |
| Fifty Day Average Change Percent | 0.09015215 |
| Fifty Two Week Change Percent | 110.19049 |
| Fifty Two Week High | 31.0 |
| Fifty Two Week High Change | -8.9 |
| Fifty Two Week High Change Percent | -0.28709677 |
| Fifty Two Week Low | 2.0 |
| Fifty Two Week Low Change | 20.1 |
| Fifty Two Week Low Change Percent | 10.05 |
| Fifty Two Week Range | 2.0 - 31.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 876,922,200,000 |
| Float Shares | 1,356,353 |
| Forward Eps | -2.46 |
| Forward P E | -8.98374 |
| Free Cashflow | -12,458,299 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 29 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.40243 |
| Gross Profits | -3,607,208 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01086 |
| Held Percent Institutions | 0.47559 |
| Implied Shares Outstanding | 1,772,199 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,754,956,800 |
| Last Split Factor | 1:50 |
| Long Business Summary | Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey. |
| Market | us_market |
| Market Cap | 39,165,600 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_32651 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -9,627,545 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 39,112,431 |
| Number Of Analyst Opinions | 3 |
| Open | 22.58 |
| Operating Cashflow | -15,869,545 |
| Operating Margins | -63.15754 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.62 |
| Phone | 609 495 2200 |
| Previous Close | 22.425 |
| Price Eps Current Year | -6.737805 |
| Price Hint | 2 |
| Price To Book | 3.3869731 |
| Price To Sales Trailing12 Months | 4.369412 |
| Profit Margins | -1.07407 |
| Quick Ratio | 2.544 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.32499886 |
| Regular Market Change Percent | -1.4492704 |
| Regular Market Day High | 22.33 |
| Regular Market Day Low | 22.1 |
| Regular Market Day Range | 22.1 - 22.33 |
| Regular Market Open | 22.58 |
| Regular Market Previous Close | 22.425 |
| Regular Market Price | 22.1 |
| Regular Market Time | 1,776,787,515 |
| Regular Market Volume | 3,199 |
| Return On Assets | -0.7026 |
| Return On Equity | -3.7867098 |
| Revenue Per Share | 7.385 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,772,199 |
| Shares Percent Shares Out | 0.1013 |
| Shares Short | 179,545 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 181,975 |
| Short Name | Palatin Technologies, Inc. |
| Short Percent Of Float | 0.1017 |
| Short Ratio | 12.59 |
| Source Interval | 15 |
| State | NJ |
| Symbol | PTN |
| Target High Price | 60.0 |
| Target Low Price | 50.0 |
| Target Mean Price | 54.33333 |
| Target Median Price | 53.0 |
| Total Cash | 14,476,162 |
| Total Cash Per Share | 8.168 |
| Total Debt | 348,788 |
| Total Revenue | 8,963,586 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -8.26 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 14.06335 |
| Two Hundred Day Average Change | 8.036651 |
| Two Hundred Day Average Change Percent | 0.5714606 |
| Type Disp | Equity |
| Volume | 3,199 |
| Website | https://palatin.com |
| Zip | 8,512 |